Recent data showed that targeting DNA sensor cyclic GMP-AMP synthase (cGAS) or NETs potentially benefitted thrombolytic therapy in patients with ischemic stroke by decreasing tPA-associated hemorrhage [118]. This evidence concerns the gene CGAS and ischemic stroke.